UAS-CLEAR dementia-care data priorities in 2026 focus on daily caregiver life, assistive-technology use, and research needs relevant to mild cognitive impairment. For people with mild cognitive impairment, the key participation questions cover cognitive goals, side-effect rules, biomarker tests, and placebo odds. UAS-CLEAR is a nationally representative longitudinal study that builds new survey tools for caregivers and links daily reports with health signals. Mild cognitive impairment means memory, language, or judgment changes beyond normal aging that do not yet prevent daily life.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who the 2026 caregiver data represent
- What researchers chose to measure in 2026
- How people with mild cognitive impairment view trial joining
- Four questions to ask before you agree
Who the 2026 caregiver data represent
The panel behind the study includes about 15,000 U.S. residents recruited by address-based sampling, according to USC's Center for Economic and Social Research USC panel description. It is housed at USC's Center for Economic and Social Research and surveys adults age 18 and older.
As of April 10, 2026, the baseline included 1,440 informal adult caregivers of adults age 50 and older, according to the a2 Collective caregiver technology findings. Most were female, over 50, and had at least some college or an associate degree. Just over one-quarter reported caring for someone with memory issues such as mild cognitive impairment or dementia.
What researchers chose to measure in 2026
The study adds smartphone assessments of daily experience plus wearables to link daily life with emotional and physiological well-being in ADRD and non-ADRD caregivers. That design keeps attention on sleep, stress, mood, activity, and care tasks as they happen.
In 2025 the a2 Collective Coordinating Center began working with USC to add questions on AI and assistive-technology use, barriers, perceived benefits and risks, evaluation priorities, and differences by caregiver and care-recipient traits. The 2026 NIA Dementia Care and Caregiving Research Summit set a wider frame, prioritizing economic impacts, community partnerships, rigorous intervention development, care models and coordination, data infrastructure, and lived experience, according to the Roybal Coordinating Center summit priorities.
How people with mild cognitive impairment view trial joining
In an online survey of 209 people with MCI, 34.1% were ready to join a cannabidiol trial and 54.5% were interested pending details, according to the FAU repository record for the BioMed Central article MCI trial willingness results. Among supporters, 71.6% would still join with a 50% chance of placebo.
That pattern matters for recruitment. Initial interest is broad, but final decisions turn on study demands, personal risk, and clear next steps.
Four questions to ask before you agree
The MCI survey result rests on only 88 completers in a CBD-specific cross-sectional survey. In that group, 67.0% accepted blood sampling for Alzheimer's pathology but only 21.6% accepted lumbar puncture.
An estimated 10%–20% of people over 65 have mild cognitive impairment, and about 10%–15% of those with MCI develop dementia each year. Ask for the visit schedule, time demands, and caregiver role in writing before consent.
- What cognitive change will the trial measure, and when?
- How are doses changed or stopped for side effects?
- Which biomarker test is required: blood draw or lumbar puncture?
- What are the placebo odds, and what follow-up care is offered?
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: A Preparation Checklist for People With Mild Cognitive Impairment
- The Ideal Dementia Care Map Discussed by NIA in 2026: What Changed and What Comes Next for Spouses and Partners
